2. Metabolic Enzyme/Protease
  3. E1/E2/E3 Enzyme
  4. MyoMed 205

MyoMed 205 is an orally active muscle ring finger protein 1 (MuRF1) inhibitor. MyoMed-205 reduces ubiquitination and subsequent proteasomal degradation of muscle proteins by inhibiting MuRF1 activity. MyoMed 205 augments muscle performance, attenuates muscle weight loss and alleviates disease-induced weight loss. MyoMed 205 can be used for the research of cancer cachexia, type 2 diabetes mellitus, and heart failure with preserved ejection fraction.

For research use only. We do not sell to patients.

MyoMed 205

MyoMed 205 Chemical Structure

CAS No. : 2614161-13-4

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

MyoMed 205 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

MyoMed 205 is an orally active muscle ring finger protein 1 (MuRF1) inhibitor. MyoMed-205 reduces ubiquitination and subsequent proteasomal degradation of muscle proteins by inhibiting MuRF1 activity. MyoMed 205 augments muscle performance, attenuates muscle weight loss and alleviates disease-induced weight loss. MyoMed 205 can be used for the research of cancer cachexia, type 2 diabetes mellitus, and heart failure with preserved ejection fraction[1][2][3].

In Vivo

MyoMed 205 (0.1% (w/w) in mouse chow Tu-205; p.o.; continuously; day 3 to day 24 post-tumor inoculation) attenuates cancer cachexia-related muscle wasting, preserves muscle function, restores mitochondrial enzyme activity, and normalizes MuRF1 and UPS stress markers in tumor-bearing C57BL/6N mice[1].
MyoMed 205 (1 g/kg; p.o.; continuously; 24 days) increases body weight, lean mass, fat content, and muscle strength in healthy C57BL/6N mice without altering food intake[1].
MyoMed 205 (1 g/kg; p.o.; diet supplementation; continuously; 28 days) significantly attenuates muscle holding impulse loss in diet-induced obese type 2 diabetic mice and normalizes their lymphocyte-granulocyte blood counts, with no significant impact on serum glucose[2].
MyoMed 205 (0.1% w/w in rat chow; p.o.; daily; 12 weeks) improves myocardial diastolic function, attenuates skeletal muscle atrophy, and restores skeletal muscle force in obese ZSF1 rats with HFpEF, while reducing pathological molecular alterations in both tissues[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6N (male, 8 months old, initial bodyweight 25.1 g, inoculated subcutaneously with B16F10 melanoma cells)[1]
Dosage: 0.1% (w/w) in mouse chow Tu-205
Administration: p.o.; continuously; day 3 to day 24 post-tumor inoculation
Result: Attenuated tumor-induced bodyweight loss to 2% at day 12 vs. 5% in untreated tumor-bearing mice.
Preserved muscle strength as measured by wire hang test holding impulses at days 9, 16, and 23.
Attenuated wasting of soleus, tibialis anterior, and extensor digitorum longus (EDL) muscles, with the greatest effect on EDL muscle mass preservation.
Attenuated epididymal fat tissue loss, protected against thymus atrophy, and reduced splenomegaly.
Restored mitochondrial citrate synthase activity in EDL muscle.
Rescued mitochondrial complex I activity in EDL muscle.
Normalized tumor-induced elevated MuRF1 protein levels in EDL muscle to control levels.
Normalized tumor-induced elevated ubiquitin K48-modified protein levels in EDL muscle to control levels.
Partially normalized tumor-induced elevated Nox2 and nitro-tyrosine (ROS stress markers) in EDL muscle.
Normalized tumor-induced depleted LC3 I/II ratio in EDL muscle to control levels.
Animal Model: C57/Bl6 (male, diet-induced obese type 2 diabetic model)[2]
Dosage: 1 g/kg
Administration: diet supplementation; continuously; 28 days
Result: Attenuated progressive loss of muscle holding impulse, with significantly improved latency time at day 28 compared to untreated mice.
Normalized lymphocyte-granulocyte ratios and absolute counts in sera, reversing diabetic stress-induced lymphopenia.
Showed no significant effects on basal serum glucose or glucose tolerance.
Animal Model: ZSF1 rats (20-week-old female, obese)[3]
Dosage: 0.1% w/w in rat chow
Administration: p.o.; daily; 12 weeks
Result: Increased EDL muscle weight normalized to tibia length compared.
Attenuated TA muscle weight loss and myofibre cross-sectional area loss.
Restored maximal absolute muscle force in EDL and soleus to levels not significantly different from lean controls.
Improved maximal specific force in EDL.
Reduced MuRF1 and Trim72 protein expression, and reduced total muscle protein ubiquitination in TA muscle.
Increased mitochondrial complex I activity, and up-regulated protein synthesis of mitochondrial complexes I-V and citrate synthase enzyme activity in TA muscle.
Down-regulated uncoupling protein 3 (UCP3) expression in TA muscle.
Improved diastolic function, including reduced E/e' ratio, left ventricular end-diastolic pressure (LVEDP), and left ventricular stiffness constant beta.
Restored left ventricular ejection fraction (LVEF) to lean control levels.
Reduced perivascular fibrosis and matrix metalloproteinase-2 (MMP2) activity.
Normalized titin phosphorylation status.
Increased left ventricular cGMP levels.
Reduced advanced glycation end-products (AGEs).
Reduced mRNA expression of ANP, collagen-1 (Col1a1), and collagen-3 (Col3a1) to levels not significantly different from lean controls.
Slightly but significantly reduced heart weight normalized to tibia length.
Produced significantly greater body weight gain over 12 weeks.
Molecular Weight

491.56

Formula

C26H25N3O5S
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C1OC2=C(C(C)=C1)C=CC(OCC3=CC=C(C(NCCNC(NCC4=CC=CS4)=O)=O)C=C3)=C2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 25 mg/mL (50.86 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.0343 mL 10.1717 mL 20.3434 mL
5 mM 0.4069 mL 2.0343 mL 4.0687 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (5.09 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.31%

SDS (251 KB)

COA (244 KB) RP-HPLC (118 KB) MS (213 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.0343 mL 10.1717 mL 20.3434 mL 50.8585 mL
5 mM 0.4069 mL 2.0343 mL 4.0687 mL 10.1717 mL
10 mM 0.2034 mL 1.0172 mL 2.0343 mL 5.0858 mL
15 mM 0.1356 mL 0.6781 mL 1.3562 mL 3.3906 mL
20 mM 0.1017 mL 0.5086 mL 1.0172 mL 2.5429 mL
25 mM 0.0814 mL 0.4069 mL 0.8137 mL 2.0343 mL
30 mM 0.0678 mL 0.3391 mL 0.6781 mL 1.6953 mL
40 mM 0.0509 mL 0.2543 mL 0.5086 mL 1.2715 mL
50 mM 0.0407 mL 0.2034 mL 0.4069 mL 1.0172 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

MyoMed 205 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

MyoMed 2052614161-13-4MyoMed205MyoMed-205E1/E2/E3 EnzymeE1 activating enzymeE2 conjugating enzymeE3 ligating enzymeUbiquitin activating enzymeUbiquitin conjugating enzymeUbiquitin ligaseMuRF1mitochondrial respiratory chainubiquitin proteasome systemcitrate synthasecomplex-1cancer cachexiamuscle protein ubiquitinationheart failure with preserved ejection fractionC57BL/6N micetype 2 diabetes mellitusInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
MyoMed 205
Cat. No.:
HY-164027
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.